TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02194244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1662 granules
Description: Single dose, oral administration of RG1662 immediate release granules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1662 granules
Description: Single dose, oral administration of RG1662 immediate release granules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RG1662 tablet
Description: Single dose, oral administration of film-coated RG1662 immediate release tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RG1662 tablet
Description: Single dose, oral administration of film-coated RG1662 immediate release tablet
Study: NCT04380415

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Single lead ambulatory ECG patch
Description: Single lead ambulatory ECG patch worn on the chest
Study: NCT02983344

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Fascia iliaca compartment block using ropivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Intravenous fentanyl

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Ultrasound-guided fascia iliaca compartment block
Study: NCT02033655

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet counseling and group education lessons
Description: Participants meet once a week for 6 months to participate in group lessons and counseling.
Study: NCT03582267

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic Acid (DHA)
Description: Daily administration of docosahexaenoic Acid (DHA). 2 grams of DHA liquid concentrate administered per day throughout trial period.
Study: NCT04407624

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent Exercise
Description: Exercise programs including warm-up, loading, cooling, and relaxation exercises are shown. The warm-up period is consist of light-paced walking, active movements of several large muscle groups. During the loading period, taking into consideration the heart rate, fatigue and shortness of breath, exercises such as walking, squat, limb movements with weights, stepping on the steps, walking on different floors are shown. Stretching exercises are done during the cooling period. Intermittent loading workouts will consist of 3-minute loads and 1-minute rest intervals. Participants are contacted every two weeks via communication methods such as e-mail, message and telephone conversation. Exercise diary is given to all patients and is taken from them at the end of the study.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Exercise programs including warm-up, loading, cooling, and relaxation exercises are shown. The warm-up period is consist of light-paced walking, active movements of several large muscle groups. In loading period, moderate aerobic exercise is consist of brisk walking to reach 60-85% of the person's maximum heart rate. Stretching exercises are done during the cooling period.
Study: NCT03009149

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Aerobic exercise will perform 3 days per week
Study: NCT02121444

Intervention type: DRUG
Intervention: Interferon beta-1b (Betaferon, BAY 86-5046)

Intervention type: DEVICE
Intervention: BETACONNECT auto-injector.
Study: NCT01798511

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nasogastric Tube Feeding
Description: A nasogastric tube will be placed into the stomach of patients.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Nutritonal Management
Description: Patients who are to have CNM will be on nil-by-mouth regimen until they either develop signs of severe AP (in which case nasojejunal tube feeding will be introduced) or the signs of AP mitigate (in which case clear liquids (as tolerated) followed by oral food (as tolerated) will be introduced)
Study: NCT01979887

Intervention type: PROCEDURE
Intervention: Meibum Expression
Description: Meibum expression as per protocol. No investigational drug is administered in this study.
Study: NCT03669822

Intervention type: OTHER
Intervention: Standard of care
Description: Care decisions driven by local physicians; this is an observational cohort.
Study: NCT01979887

Intervention type: PROCEDURE
Intervention: Meibum Expression
Description: Meibum expression as per protocol. No investigational drug is administered in this study.

Intervention type: PROCEDURE
Intervention: Meibum Expression
Description: Meibum expression as per protocol. No investigational drug is administered in this study.
Study: NCT00718952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vardenafil
Description: vardenafil tablet 5mg once-daily orally in the first 4 weeks while 5mg twice-daily orally in the following 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet 5mg once-daily orally in the first 4 weeks while 5mg twice-daily orally in the following 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vardenafil
Description: Patients in all the 2 arms will take vardenafil tablet 5mg twice-daily orally from week 13 to week 24(open-label).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vardenafil
Description: Patients in all the 2 arms will take vardenafil tablet 5mg twice-daily orally from week 13 to week 24(open-label).
Study: NCT02862171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapivirine Vaginal Ring-004
Description: To assess the safety profile of the 25 mg Dapivirine Vaginal Ring-004, when inserted at monthly intervals, in an open-label trial
Study: NCT03615378

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 5000 IU D3
Description: Daily

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 1000 IU D3
Description: Daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: lactose/sugar tablet
Study: NCT05282862

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Horizontal bone augmentation
Description: Horizontal bone augmentation of a limited span (1-2 teeth) edentulous ridge with neighboring teeth present.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Horizontal bone augmentation
Description: Horizontal bone augmentation of a limited span (1-2 teeth) edentulous ridge with neighboring teeth present.
Study: NCT02473432

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RMT + usual care
Description: Respiratory muscle training is performed with the Orygen Dual valve (inspiratory and espiratory trainer)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NMES
Description: Neuromuscular electrical stimulation is performed with the Vital Stim ® device (approved by the FDA for dysphagia treatment). It consists in the placement of two electrodes located in suprahyoid muscles as above described.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Standard swallow therapy consists of physiotherapy, occupational therapy and speech therapy targeting specific swallow impairments. In the case of dysphagia, the standard pattern includes measures to protect the airway and compensatory techniques.
Study: NCT02764060

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tongue scraper
Description: The patients were instructed to start cleaning the tongue by two pulling strokes along the median sulcus of the tongue, followed by two pulling strokes along the lateral edges of the tongue.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toothbrush
Description: The patients who were assigned to the tooth brush group were taught to perform three forward and backward strokes along the median sulcus and at each lateral part of the tongue.
Study: NCT00844896

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DEF-only
Description: The DEF protocol is from the National Child Traumatic Stress Network (NCTSN). DEF provides a sequential methodology for clinicians to assess medically traumatized children and their families and to plan specific interventions for them.~In the present study, the DEF intervention is both a generalized approach taught to all Shriners Hospitals for Children (SHC)- Boston clinical staff, and for those participants of the present study, consists of an optional meeting with a member of the SHC Psychiatry Department. During this meeting, parents will have the chance to review any areas of pain, anxiety, or support that came up during their interviews or any other areas of concern about their child or his/her hospitalization that they wish to raise.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DEF + COPE
Description: All enrolled participants will be offered the chance to meet with a psychiatric clinician for the DEF component of the intervention.~For those assigned to receive COPE (Creating Opportunities for Parent Empowerment), parents will receive one of two versions of the materials: one for children less than one year old, and one for children ages 1-5 years. The COPE program was adapted for children with burns and developed to target major stressors that parents experience when their children are hospitalized, such as the loss of parental control. COPE also contains a behavioral component to help parents to carry out the recommendations provided to them. Each of these versions of the COPE program is essentially self-administered to parents via audio tapes and activity workbooks.
Study: NCT00701675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sertraline 50 mg daily
Description: 50 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sertraline 100 mg daily
Description: 100 mg daily
Study: NCT01603979

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV-203
Description: The antibody AV-203 is a humanized immunoglobulin G1/kappa (IgG1/κ) monoclonal antibody that targets the receptor tyrosine kinase (RTK) ERBB3 and inhibits ERBB3 activities. AV-203 will be administered as a 60 to 75-minute IV infusion once every 2 weeks until disease progression or unacceptable toxicity.
Study: NCT03119441

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dental Water Jet
Description: Dental Water Jet will be used by subjects to clean their teeth in the interproximal areas.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dental Floss
Description: Dental Floss will be used by subjects to clean their teeth in the interproximal areas.
Study: NCT01451866

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: resistance training
Description: hypertrophic resistance training
Study: NCT03210688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Tablet prednisolone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Tablet prednisolone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alfacalcidol
Description: Capsule alfacalcidol 0,5 microgram/day
Study: NCT01776697

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pelubiprofen (30mg) tablet IR

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pelubiprofen (30mg) tablet IR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pelubiprofen SR (as a pelubiprofen 90 mg) tablet
Study: NCT02906566

Intervention type: DRUG
Group type: OTHER
Intervention: Retinol
Description: Retinol in the form of vitamin A lotion

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo of Retinol
Study: NCT01831401

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Operating table position 0° head down (Horizontal)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Operating table position 0° head down (Horizontal)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Operating table position 0° head down (Horizontal)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Operating table position 7° head down.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Operating table position 7° head down.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Operating table position 7° head down.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Operating table position Y° head down
Description: Operating table position Y° head down (angle required to obtain vertical Transverse Pelvis Lines).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Operating table position Y° head down
Description: Operating table position Y° head down (angle required to obtain vertical Transverse Pelvis Lines).
Study: NCT01451866

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: complex resistance training
Description: complex resistance training with speed, excentric and power-endurance elements
Study: NCT01831401

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Operating table position Y° head down
Description: Operating table position Y° head down (angle required to obtain vertical Transverse Pelvis Lines).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard straight acetabular component introducer without alignment guide.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard straight acetabular component introducer without alignment guide.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard straight acetabular component introducer without alignment guide.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified 35° acetabular component introducer.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified 35° acetabular component introducer.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified 35° acetabular component introducer.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inclinometer-assisted acetabular component introducer.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inclinometer-assisted acetabular component introducer.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inclinometer-assisted acetabular component introducer.
Study: NCT00426361

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix ® Polio
Description: One dose of vaccine administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix ® Polio
Description: One dose of vaccine administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' HPV-16/18 L1 AS04 vaccine (Cervarix TM)
Description: Three doses of vaccine administered intramuscularly, with the second and third dose give one month and six months after the first dose respectively

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' HPV-16/18 L1 AS04 vaccine (Cervarix TM)
Description: Three doses of vaccine administered intramuscularly, with the second and third dose give one month and six months after the first dose respectively

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' HPV-16/18 L1 AS04 vaccine (Cervarix TM)
Description: Three doses of vaccine administered intramuscularly, with the second and third dose give one month and six months after the first dose respectively
Study: NCT01359969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhC1INH
Description: Patients up to 84 kg will receive one i.v. injection of Ruconest at a dose of 50 U/kg. The reconstituted solution should be administered as a slow i.v. injection over approximately 5 minutes. Patients of 84 kg body weight or greater will receive one i.v. injection of Ruconest at the dose of 4200 U (2 vials).
Study: NCT02653430

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy
Description: After complete exams such as EKG，UCG，spirometry and other basic exams,estimate the condition of patient whether he(she) can tolerate a surgical operation.Then we operate theSleeve gastrectomy laparoscopically by a group of experienced surgeons.
Study: NCT02149108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib (BIBF 1120)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BSC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BSC
Study: NCT02078427

Intervention type: BIOLOGICAL
Intervention: ADVATE
Description: Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method

Intervention type: BIOLOGICAL
Intervention: ADVATE
Description: Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method

Intervention type: BIOLOGICAL
Intervention: ADYNOVI
Description: Antihemophilic Factor (Recombinant) Pegylated

Intervention type: BIOLOGICAL
Intervention: ADYNOVI
Description: Antihemophilic Factor (Recombinant) Pegylated
Study: NCT03052218

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pupillometry
Description: Pupillometry performed before administration of tramadol, at T0 and then 1 to twice per hour, during the stay of the patient in the emergency department
Study: NCT04096508

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music listening
Description: Patients sit comfortably in a chair for 20 min listening music before the procedure.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music listening
Description: Patients sit comfortably in a chair for 20 min listening music before the procedure.
Study: NCT02455050

Intervention type: DRUG
Group type: OTHER
Intervention: Carboxymethylcellulose Sodium Based Eye Drops
Description: 1 to 2 drops of Carboxymethylcellulose Sodium Based Eye Drops \[New Eye Drop Formula\] in each eye.

Intervention type: DRUG
Group type: OTHER
Intervention: Carboxymethylcellulose Sodium Based Eye Drops
Description: 1 to 2 drops of Carboxymethylcellulose Sodium Based Eye Drops \[New Eye Drop Formula\] in each eye.

Intervention type: DRUG
Group type: OTHER
Intervention: Carboxymethylcellulose Sodium Based Eye Drops
Description: 1 to 2 drops of Carboxymethylcellulose Sodium Based Eye Drops \[New Eye Drop Formula\] in each eye.

Intervention type: DRUG
Group type: OTHER
Intervention: Carboxymethylcellulose Sodium Based Eye Drops
Description: 1 to 2 drops of Carboxymethylcellulose Sodium Based Eye Drops \[New Eye Drop Formula\] in each eye.

Intervention type: DRUG
Group type: OTHER
Intervention: Systane® Gel Drops
Description: 1 to 2 drops of Systane® Gel Drops in each eye.

Intervention type: DRUG
Group type: OTHER
Intervention: Systane® Gel Drops
Description: 1 to 2 drops of Systane® Gel Drops in each eye.

Intervention type: DRUG
Group type: OTHER
Intervention: Genteal® Lubricant Gel Drops
Description: 1 to 2 drops of Genteal® Lubricant Gel Drops in each eye.

Intervention type: DRUG
Group type: OTHER
Intervention: Genteal® Lubricant Gel Drops
Description: 1 to 2 drops of Genteal® Lubricant Gel Drops in each eye.
Study: NCT01783548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BDP Nasal Aerosol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01326676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polypill: Red Heart Pill
Description: The polypill will be taken once/day in the form of a hard capsule, to be taken orally. There are two versions of the polypill (Red Heart Pill):~Version 1 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Atenolol 50mg; Version 2 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Hydrochlorothiazide 12.5mg.~Red Heart Pill Version 1 and Red Heart Pill Version 2. In general, participants with a history of coronary heart disease will be given version 1, and those with a history of stroke or cerebrovascular disease will be given version 2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual medication
Description: Participants in the 'Usual Care' arm will continue to take the separate, individual medications prescribed by their usual doctor, e.g. aspirin, blood pressure lowering drugs, statins.
Study: NCT00324740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isotretinoin
Description: Given orally
Study: NCT04644965

Intervention type: DIAGNOSTIC_TEST
Intervention: CombynTM Function & Spaces ECG
Description: Multi-frequency impedance measurement to assess the muscle and fat mass

Intervention type: DIAGNOSTIC_TEST
Intervention: CombynTM Function & Spaces ECG
Description: Multi-frequency impedance measurement to assess the muscle and fat mass

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Taking
Description: Sampling of blood of the finger pad to assess liver function

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Taking
Description: Sampling of blood of the finger pad to assess liver function

Intervention type: DIAGNOSTIC_TEST
Intervention: Spiroergometry
Description: Spiroergometry to assess cardiopulmonary capacity. The intensity will be raised in steps until total exhaustion. In between each step we will take blood of the ear lobe to determine the lactate level

Intervention type: DIAGNOSTIC_TEST
Intervention: Spiroergometry
Description: Spiroergometry to assess cardiopulmonary capacity. The intensity will be raised in steps until total exhaustion. In between each step we will take blood of the ear lobe to determine the lactate level

Intervention type: DIAGNOSTIC_TEST
Intervention: Dordel Koch Test (DKT)
Description: Dordel Koch Test (DKT) to evaluate the motor activity. The DKT is a heterogeneous test battery for children and adolescents and consists of seven parts: lateral jumping, sit and reach, situps, long stand jump, one-legged stand, push-ups and 6-min-run

Intervention type: DIAGNOSTIC_TEST
Intervention: Dordel Koch Test (DKT)
Description: Dordel Koch Test (DKT) to evaluate the motor activity. The DKT is a heterogeneous test battery for children and adolescents and consists of seven parts: lateral jumping, sit and reach, situps, long stand jump, one-legged stand, push-ups and 6-min-run

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Ultrasound for abdominal wall muscles

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Ultrasound for abdominal wall muscles

Intervention type: DIAGNOSTIC_TEST
Intervention: Stance and gait analyses
Description: Stance and gait analyses for measuring the core stability

Intervention type: DIAGNOSTIC_TEST
Intervention: Stance and gait analyses
Description: Stance and gait analyses for measuring the core stability
Study: NCT00653328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atrasentan hydrochloride
Description: Atrasentan 10 mg orally everyday continuously beginning on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxil
Description: 50 mg/m2 intravenously every 28 days
Study: NCT04315597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laif® 900, BAY98-7108
Description: 1 x daily, 1 tablet, 900 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 x daily, 1 tablet, 900 mg
Study: NCT03732521

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational therapy
Description: educational intervention to the caregiver and individualization according to their family and social context